We are live on ! Find out more
AUTL

Autolus Therapeutics
AUTL

Fund managers haven’t disclosed any holdings of AUTL yet.

AUTL Hedge Fund Activity: Q1 2026 in Review

84 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2026, worth a combined $184M — down 33% from $277M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of AUTL and 9 opened new positions — a net loss of 3 holders — while 30 trimmed existing stakes and 22 added.

The largest buyer was MAK Capital One, adding an estimated $5.49M. The largest seller was BlackRock, cutting an estimated $3.35M.

  • 84 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2026, down from 89 in Q4 2025.
  • Funds reported $184M of Autolus Therapeutics stock for Q1 2026, down 33% quarter-over-quarter.
  • 9 funds opened new Autolus Therapeutics positions in Q1 2026 and 12 closed out, a net change of -3 holders.
  • The largest Autolus Therapeutics buyer in Q1 2026 was MAK Capital One, an estimated $5.49M added.
  • The largest Autolus Therapeutics seller in Q1 2026 was BlackRock, an estimated $3.35M sold.

Based on aggregated 13F filings for Q1 2026.